Friday 6 November 2026
Export MDLN’s income statement to Excel — free account
Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.
- Revenue
- +14.1%
- Free cash flow
- +916.1%
- Total debt
- −23.7%
Quarter to September 2026, against a year earlier
38.99
0.77
−1.94%
Follow MDLN
Alert me
Medline Inc. (MDLN) Revenue
Medline Inc.'s revenue for fiscal 2025 was $28.4B, up 11.5% from $25.5B in fiscal 2024. Over the twelve months to 30 September 2026 it was $30.7B. Medline Inc. ranks 1st of 47 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $28.4B | 11.47% |
| FY2024 | $25.5B | 9.80% |
| FY2023 | $23.2B | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $7.9B | 2.23% |
| Jun 2026 | $7.7B | 4.53% |
| Mar 2026 | $7.4B | (5.59%) |
| Dec 2025 | $7.8B | 13.08% |
| 2 more quarters | Free account |
Revenue against peers
| Company | Revenue |
|---|---|
| MDLN Medline Inc. | $30.7B |
| BDX Becton, Dickinson and Company compare | $20.8B |
| BAX Baxter International Inc. compare | $11.6B |
| ISRG Intuitive Surgical, Inc. compare | $11.6B |
| ALC Alcon compare | $10.9B |
| SOLV Solventum Corporation compare | $8.2B |
| RMD ResMed Inc. compare | $5.7B |
| COO The Cooper Companies, Inc. compare | $4.2B |
| WST West Pharmaceutical Services, Inc. compare | $3.4B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on MDLN
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Book value per share
- The full statement